Clinical Efficacy and Safety of Bevacizumab, Apatinib, and Recombinant Human Endothelial Inhibitor in the Treatment of Advanced Gastric Cancer

Table 5

Comparison of serum tumor marker levels before and after treatment in the four groups (‾x ± s, mg/L).

Groups	n	CEA		CA199
		Before treatment	After treatment	Before treatment	After treatment
Control group	51	67.51 ± 13.48	33.14 ± 5.53	436.75 ± 52.64	246.34 ± 30.01
Study group I	51	68.31 ± 12.37	18.47 ± 5.34^a	431.79 ± 48.99	185.37 ± 26.51^a
Study group II	51	68.49 ± 11.64	10.36 ± 6.13^a	435.17 ± 49.61	163.74 ± 27.16^a
Study group III	51	67.99 ± 12.08	17.97 ± 5.83^a	434.64 ± 50.36	190.34 ± 29.44^a
F		88.233	141.582	73.213	78.839
		0.021	<0.001	0.011	<0.001

, in the comparison with pretreatment. ^a, in the comparison between the study groups and the control group after treatment.